Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

Using 0.1% Alfatradiol and 1% Pyrilutamide stopped hair loss, reducing shedding from over 150 hairs a day to less than 10, with no side effects. The user also uses Minoxidil and microneedling, applying the treatments twice daily.

The conversation discusses choosing between titanium fixed needles and a pen with disposable needles for hair loss treatment at a 1.5mm depth. The preference is for disposable needles for better sanitization.

The user is experiencing diffuse thinning and has tried treatments like topical and oral finasteride, oral dutasteride, topical minoxidil, microneedling, melatonin, and caffeine without success. Despite using these treatments for over four years, the user reports continued hair thinning and is considering trying RU58841.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Hair loss discussion focused on Fluridil treatment. Availability of higher concentrations questioned.

A 30-year-old with diffuse thinning and a balding crown is using a treatment regimen of a 2-in-1 pill containing finasteride, minoxidil, and biotin, along with various supplements. After two weeks, no side effects have been experienced, and updates with pictures will be posted monthly.

The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.

Fluridil should not be mixed with minoxidil due to water content. Mixing with stemoxydine or alfatradiol is being considered for easier application.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.

1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.

The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The user had a hair transplant with 2000 grafts in the frontal and mid-scalp areas and has been using finasteride and minoxidil for 3 months. The crown area is expected to improve with continued treatment, and results are generally positive so far.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

The user has severe diffuse thinning on the scalp and is using finasteride, topical minoxidil, dermarolling, tretinoin, and Nizoral without satisfactory results. They are considering a hair transplant but are concerned about the cost and the number of grafts needed.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.